Chemo plus immunotherapy before and after surgery for stomach/esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of chemotherapy (FLOT) plus an immunotherapy drug (durvalumab) before and after surgery for stomach or esophageal cancer that can be removed. The goal is to see if adding durvalumab helps improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stomach, gastroesophageal junction, or lower esophageal cancer that is locally advanced (has spread to nearby lymph nodes but not to distant organs) and is considered operable.
- You are at least 18 years old and in relatively good health (ECOG performance score 0 or 1), meaning you can carry out your daily activities without much help.
- You have not received chemotherapy, radiation, or immunotherapy for this cancer, or any other cancer within the past 5 years.
- You do not have serious lung, heart, or autoimmune conditions, and you do not have an active infection that is not well controlled.
- You are willing to use effective contraception during treatment and for several months after, and if you are a woman of childbearing potential, you must have a negative pregnancy test before starting.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding an immunotherapy drug called durvalumab to two different chemotherapy combinations before surgery for stomach or gastroesophageal junction cancer. The goal is to see if these combinations shrink tumors more effectively and improve outcomes.
This trial tests adding an immunotherapy drug (tislelizumab) to standard chemotherapy (FLOT) before surgery for people with stomach or esophagus cancer that can be removed but hasn't spread. The goal is to see if this combination is safe and works better than chemotherapy alone.
This trial tests a combination of chemotherapy, radiation, and an immunotherapy drug (durvalumab) for esophageal cancer that has spread to a few other places in the body or is too advanced for surgery. It aims to see if this combination helps with swallowing difficulties and slows the cancer's growth.
This trial tests whether combining immunotherapy with chemotherapy before surgery can help treat adenocarcinoma of the esophagus and stomach junction. It aims to improve outcomes for patients whose cancer can be surgically removed.
This trial tests combining chemotherapy (FOLFOX) with an immunotherapy drug (Toripalimab) before and after surgery for a type of stomach cancer called HER2-negative adenocarcinoma of the esophagogastric junction. It may help shrink the tumor and improve outcomes.
This trial tests a combination of chemotherapy (DOS) plus an immunotherapy drug (Adebrelimab) given before surgery for people with locally advanced stomach or gastroesophageal junction cancer. The goal is to see if the treatment shrinks the tumor and improves outcomes.
Hear when a new Esophagogastric Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.